8-[4-[4-(4-氯苯基)哌嗪-1-磺酰基)苯基]-1-丙基黄嘌呤 | 1092351-10-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 8-[4-[4-(4-氯苯基)哌嗪-1-磺酰基)苯基]-1-丙基黄嘌呤
• 英文名称: PSB-603
• 英文别名: 8-(4-(4-(4-chlorophenyl)piperazine-1-sulfonyl)phenyl)-1-propylxanthine；[3H]-PSB-603；8-(4-(4-(4-chlorophenyl)piperazide-1-sulfonyl)phenyl)-1-propylxanthine；[3H]-8-(4-(4-(4-chlorophenyl)piperazine-1-sulfonyl)phenyl)-1-propylxanthine；8-{4-[4-(4-chlorophenyl)piperazine-1-sulfonyl]phenyl}-1-propyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione；8-[4-[4-(4-chlorophenyl)piperazin-1-yl]sulfonylphenyl]-1-propyl-3,7-dihydropurine-2,6-dione
• CAS: 1092351-10-4
• 化学式: C₂₄H₂₅ClN₆O₄S
• 分子量: 529.019
• InChiKey: OVHCTHHFOHMNFV-UHFFFAOYSA-N

物化性质

• 熔点：
  >298 °C (decomp)
• 密度：
  1.430±0.06 g/cm3(Predicted)
• 溶解度：
  在DMSO中溶解至50mM

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-(4-氯苯基)哌嗪 、 1-propyl-8-[4-[[[p-nitrophenyl]oxy]sulfonyl]phenyl]xanthine 在 ammonium hydroxide 、 水 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 49.33h， 以62%的产率得到8-[4-[4-(4-氯苯基)哌嗪-1-磺酰基)苯基]-1-丙基黄嘌呤
  参考文献：
  名称：

  1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and Characterization of Adenosine A_2B Receptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype Specificity

  摘要：

  A new series of 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines was designed, synthesized, and characterized in radioligand binding and functional assays at A(2B) adenosine receptors. A(2B) antagonists with subnanomolar affinity and high selectivity were discovered. The most potent compounds were 1-ethyl-8-(4-(4-(4-trifluoromethylbenzyl)piperazine-1-sulfonyl)phenyl)xanthine (24, PSB-09120, K-i (human A(2B)) = 0. 157 nM) and 8-(4-(4-(4-chlorobenzyl)piperazine-1-sulfonyl)phenyl)-1-propylxanthine (17, PSB-0788, K-i (human A2(B)) = 0.393 nM). Moreover, 8-(4-(4-(4-chlorophenyl)piperazine-1-sulfonyl)phenyl)-1-propylxanthine (35, PSB-603) was developed as an A(2B)-specific antagonist exhibiting a Ki value of 0.553 nM at the human A2B receptor and virtually no affinity for the human and rat A(1) and A(2A) and the human A(3) receptors up to a concentration of 10 mu M. A tritiated form of the compound was prepared as a new radioligand and characterized in kinetic, saturation, and competition studies. It was shown to be a useful pharmacological tool for the selective labeling of human as well as rodent A(2B) receptors (K-D human A(2B) 0.403 nM, mouse A(2B) 0.351 nM).

  DOI：

  10.1021/jm900413e

文献信息

• Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
  申请人：Yeda Research and Development Co. Ltd

  公开号：US10618963B2

  公开（公告）日：2020-04-14

  The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

  本说明书公开了一种药物组合物，该药物组合物包含一种活性剂，可降低个体的全身免疫抑制水平，用于治疗中枢神经系统的疾病、紊乱、病症或损伤。该药物组合物通过一个剂量方案给药，该剂量方案包括至少一个疗程，每个疗程依次包括一个治疗疗程和一个非治疗间隔疗程。
• Adenosine receptor antagonists and uses thereof
  申请人：Teon Therapeutics, Inc.

  公开号：US11124515B2

  公开（公告）日：2021-09-21

  Disclosed herein are compounds of Formula (III), compositions and formulations thereof, and methods for modulating the A22B adenosine receptor for treatment of A2B adenosine receptor mediated diseases or conditions.

  本文公开了式（III）化合物及其组合物和制剂、 以及调节 A22B 腺苷受体以治疗 A2B 腺苷受体介导的疾病或病症的方法。
• Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS
  申请人：Yeda Research and Development Co. Ltd

  公开号：US11492405B2

  公开（公告）日：2022-11-08

  The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

  本说明书公开了一种药物组合物，该药物组合物包含一种活性剂，可降低个体的全身免疫抑制水平，用于治疗中枢神经系统的疾病、紊乱、病症或损伤。 该药物组合物通过一个剂量方案给药，该剂量方案包括至少一个疗程，每个疗程依次包括一个治疗疗程和一个非治疗间隔疗程。
• REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS
  申请人：Yeda Research and Development Co. Ltd

  公开号：EP3509636A1

  公开（公告）日：2019-07-17
• Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Alzheimer's Disease
  申请人：Yeda Research and Development Co. Ltd

  公开号：US20160297880A1

  公开（公告）日：2016-10-13

  A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.